Enhancement of transgene expression from viral-based vaccine vecors by expression of suppressors of the type i interferon response

Abstract

Viral-based vectors are genetically engineered to express inhibitors of the anti-viral immune system (e.g. inhibitors of the type I interferon response) in order to enhance transgene expression. The transgenes may encode antigens or other therapeutic agents.

Description

technical field [0001] The present invention generally relates to the enhancement of transgene expression from viral-based vectors. In particular, the present invention provides viral-based vectors encoding genetically engineered inhibitors of the type I interferon response, as well as studies that provide host cell active responses (e.g., immunostimulatory, therapeutic, or selective apoptotic responses) ) genes, thereby enhancing transgene expression. Background technique [0002] The innate immune system acts as the first line of defense against invasive pathogens, including bacteria or viruses. Eukaryotic cells are expressed via numerous cell surface and intracellular germline-encoded pattern recognition receptors (PRRs) such as Toll-like receptors (TLRs), Nod-like (nucleotide-binding oligomerization domain) receptors, and RNA unwinding The enzymes RIG-I (retinoic acid-inducible gene-I) and MDA5 (melanoma differentiation-associated gene 5) have an intrinsic ability to r...

AI Technical Summary

Problems solved by technology

This is often due to the inability of host cells infected by the vaccine vector to distinguish the viral infectious agent from the attenuated viral vaccine vector

When the vaccine viral vector will become a real infectious agent, the host cells will respond to it: the cells initiate an immune response, especially an IFN I response, which destroys or attenuates the ability of the vaccine vector to produce the encoded antigen, thus making the vaccine administration difficult. failure of purpose

Images